To end the COVID-19 pandemic and save lives, the world needs quality COVID-19 treatments. It is critical that regulators and manufacturers ensure therapeutics meet quality expectations. The antiviral drug VEKLURY (remdesivir) is the first U.S. Food and Drug Administration approved treatment for hospitalized COVID-19 patients. Healthcare providers around the globe are using remdesivir not only to treat patients, but also in clinical trials.
As part of our ongoing COVID-19 response, USP has developed the USP Methods to Assist in Detecting Falsified Remdesivir to reduce risks from substandard and falsified remdesivir. These methods can assist regulators and quality control laboratories to help ensure quality remdesivir is being approved, procured and distributed.